167 related articles for article (PubMed ID: 38427280)
21. Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study.
Yuki S; Yamazaki K; Sunakawa Y; Taniguchi H; Bando H; Shiozawa M; Nishina T; Yasui H; Kanazawa A; Ando K; Horita Y; Goto M; Okano N; Moriwaki T; Satoh T; Tsuji A; Yamashita K; Asano C; Abe Y; Nomura S; Yoshino T
Clin Colorectal Cancer; 2024 Jun; 23(2):147-159.e7. PubMed ID: 38331650
[TBL] [Abstract][Full Text] [Related]
22. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.
Van Cutsem E; Joulain F; Hoff PM; Mitchell E; Ruff P; Lakomý R; Prausová J; Moiseyenko VM; van Hazel G; Cunningham D; Arnold D; Schmoll HJ; Ten Tije AJ; McKendrick J; Kröning H; Humblet Y; Grávalos C; Le-Guennec S; Andria M; Dochy E; Vishwanath RL; Macarulla T; Tabernero J
Target Oncol; 2016 Jun; 11(3):383-400. PubMed ID: 26706237
[TBL] [Abstract][Full Text] [Related]
23. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.
Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F
Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741
[TBL] [Abstract][Full Text] [Related]
24. Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
Coutzac C; Trouilloud I; Artru P; Henriques J; Masson T; Doat S; Bouché O; Coriat R; Saint A; Moulin V; Vernerey D; Gallois C; De La Fouchardière C; Tougeron D; Taieb J
Clin Colorectal Cancer; 2022 Jun; 21(2):132-140. PubMed ID: 35337742
[TBL] [Abstract][Full Text] [Related]
25. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
[TBL] [Abstract][Full Text] [Related]
26. Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
Kehmann L; Berres ML; Gonzalez-Carmona M; Modest DP; Mohr R; Wree A; Venerito M; Strassburg C; Keitel V; Trautwein C; Luedde T; Roderburg C
BMC Cancer; 2023 May; 23(1):470. PubMed ID: 37217885
[TBL] [Abstract][Full Text] [Related]
27. Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS).
Hamers PAH; Vink GR; Elferink MAG; Stellato RK; Dijksterhuis WPM; Punt CJA; Koopman M; May AM;
Clin Colorectal Cancer; 2022 Jun; 21(2):154-166. PubMed ID: 35474007
[TBL] [Abstract][Full Text] [Related]
28. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
Kashiwa M; Matsushita R
Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433
[TBL] [Abstract][Full Text] [Related]
29. Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
Hamaguchi T; Denda T; Kudo T; Sugimoto N; Ura T; Yamazaki K; Fujii H; Kajiwara T; Nakajima TE; Takahashi S; Otsu S; Komatsu Y; Nagashima F; Moriwaki T; Esaki T; Sato T; Itabashi M; Oki E; Sasaki T; Chiron M; Yoshino T
Cancer Sci; 2019 Nov; 110(11):3565-3572. PubMed ID: 31520559
[TBL] [Abstract][Full Text] [Related]
30. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
31. Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors.
Varghese AM; Cardin DB; Hersch J; Benson AB; Hochster HS; Makris L; Hamada K; Berlin JD; Saltz LB
Clin Cancer Res; 2020 Apr; 26(7):1555-1562. PubMed ID: 31924737
[TBL] [Abstract][Full Text] [Related]
32. A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
Jo H; Lee MS; Lee YP; Kim H; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim ST
Clin Oncol (R Coll Radiol); 2022 Aug; 34(8):e323-e328. PubMed ID: 35248464
[TBL] [Abstract][Full Text] [Related]
33. A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial.
Izawa N; Masuishi T; Takahashi N; Shoji H; Yamamoto Y; Matsumoto T; Sugiyama K; Kajiwara T; Kawakami K; Aomatsu N; Kondoh C; Kawakami H; Takegawa N; Esaki T; Shimokawa M; Nishio K; Narita Y; Hara H; Sunakawa Y; Boku N; Moriwaki T; Eguchi Nakajima T; Muro K
Target Oncol; 2023 May; 18(3):369-381. PubMed ID: 37148491
[TBL] [Abstract][Full Text] [Related]
34. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J
J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725
[TBL] [Abstract][Full Text] [Related]
35. Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
Masuishi T; Taniguchi H; Kawakami T; Kawamoto Y; Kadowaki S; Onozawa Y; Muranaka T; Tajika M; Yasui H; Nakatsumi H; Yuki S; Muro K; Omae K; Komatsu Y; Yamazaki K
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392174
[TBL] [Abstract][Full Text] [Related]
36. Aflibercept: A Review in Metastatic Colorectal Cancer.
Syed YY; McKeage K
Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913
[TBL] [Abstract][Full Text] [Related]
37. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan BM; Hochster HS; Lenz HJ
Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
Yamazaki K; Nagase M; Tamagawa H; Ueda S; Tamura T; Murata K; Eguchi Nakajima T; Baba E; Tsuda M; Moriwaki T; Esaki T; Tsuji Y; Muro K; Taira K; Denda T; Funai S; Shinozaki K; Yamashita H; Sugimoto N; Okuno T; Nishina T; Umeki M; Kurimoto T; Takayama T; Tsuji A; Yoshida M; Hosokawa A; Shibata Y; Suyama K; Okabe M; Suzuki K; Seki N; Kawakami K; Sato M; Fujikawa K; Hirashima T; Shimura T; Taku K; Otsuji T; Tamura F; Shinozaki E; Nakashima K; Hara H; Tsushima T; Ando M; Morita S; Boku N; Hyodo I
Ann Oncol; 2016 Aug; 27(8):1539-46. PubMed ID: 27177863
[TBL] [Abstract][Full Text] [Related]
39. Aflibercept.
Ciombor KK; Berlin J; Chan E
Clin Cancer Res; 2013 Apr; 19(8):1920-5. PubMed ID: 23444216
[TBL] [Abstract][Full Text] [Related]
40. An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer.
Mizukami T; Minashi K; Hara H; Nishina T; Amanuma Y; Takahashi N; Nakasya A; Takahashi M; Nakajima TE
Invest New Drugs; 2022 Jun; 40(3):614-621. PubMed ID: 35278170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]